Prevalence of Apparent Treatment‐Resistant Hypertension in the United States According to the 2017 High Blood Pressure Guideline

[1]  M. Hall.  National Heart, Lung, and Blood Institute , 2020, The Grants Register 2021.

[2]  David A Calhoun,et al.  Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. , 2018, Hypertension.

[3]  P. Greenland,et al.  Estimating the Association of the 2017 and 2014 Hypertension Guidelines With Cardiovascular Events and Deaths in US Adults: An Analysis of National Data , 2018, JAMA cardiology.

[4]  Wilbert S Aronow,et al.  2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2018, Hypertension.

[5]  Daniel W. Jones,et al.  Potential US Population Impact of the 2017 ACC/AHA High Blood Pressure Guideline , 2018, Circulation.

[6]  M. Fornage,et al.  Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association , 2017, Circulation.

[7]  C. Ayers,et al.  Comparison of Morisky Medication Adherence Scale with therapeutic drug monitoring in apparent treatment-resistant hypertension. , 2015, Journal of the American Society of Hypertension : JASH.

[8]  S. Frey,et al.  Systematic review and meta-analysis of the prevalence of resistant hypertension in treated hypertensive populations. , 2015, American journal of hypertension.

[9]  B. Davis,et al.  Treatment-Resistant Hypertension and the Incidence of Cardiovascular Disease and End-Stage Renal Disease: Results From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) , 2014, Hypertension.

[10]  S. Oparil,et al.  Incident ESRD and treatment-resistant hypertension: the reasons for geographic and racial differences in stroke (REGARDS) study. , 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[11]  C. Ayers,et al.  Therapeutic drug monitoring facilitates blood pressure control in resistant hypertension. , 2014, Journal of the American College of Cardiology.

[12]  Deepak L. Bhatt,et al.  Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis. , 2012, European heart journal.

[13]  G. Bakris,et al.  Resistant hypertension—its identification and epidemiology , 2013, Nature Reviews Nephrology.

[14]  W. Elliott.  Uncontrolled and Apparent Treatment Resistant Hypertension in the United States, 1988 to 2008 , 2012 .

[15]  B. Egan,et al.  Uncontrolled and Apparent Treatment Resistant Hypertension in the United States, 1988 to 2008 , 2011, Circulation.

[16]  Stephen D. Persell.  Prevalence of Resistant Hypertension in the United States, 2003–2008 , 2011, Hypertension.

[17]  R. Gillum,et al.  Association of hypertension treatment and control with all-cause and cardiovascular disease mortality among US adults with hypertension. , 2010, American journal of hypertension.

[18]  D. Goff,et al.  Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. , 2008, Circulation.

[19]  Daniel W. Jones,et al.  A Scientific Statement From the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research , 2008 .

[20]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.